Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
Retrieved on:
Tuesday, December 20, 2022
The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
Key Points:
- The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart.
- In fact, the mRNA vaccine generates superior T cell responses.
- Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and generated T cell and antibody responses.
- "I am overwhelmed by these results" says Dr. Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines.